Effect of a selective cyclooxygenase type 2 inhibitor celecoxib on depression associated with obesity in mice: An approach using behavioral tests

Neurochemical Research

Volumn 39, Issue 7, 2014, Pages 1395-1402

  Kurhe, Yeshwant ^a   Mahesh, Radhakrishnan ^a   Gupta, Deepali ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

COX 2; Depression; Insulin resistance; Obesity; Plasma glucose

Indexed keywords

CELECOXIB; CHOLESTEROL; ESCITALOPRAM; GLUCOSE; TRIACYLGLYCEROL; ANTIDEPRESSANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ELEVATED PLUS MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; FORCED SWIM TEST; GLUCOSE BLOOD LEVEL; IMMOBILIZATION; LIPID DIET; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSION; MALE; MICE; MOTOR ACTIVITY; OBESITY; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84904541466     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1322-2     Document Type: Article

References (43)

1. Lopez AD, Murray CC (1998) The global burden of disease, 1990-2020. Nat Med 11:1241-1243 (Pubitemid 28512100)
2. Simon GE, Von-Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, Kessler RC (2006) Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 63:824-830
3. Vogelzangs N, Kritchevsky SB, Beekman AT, Brenes GA, Newman AB, Satterfield S, Penninx BW (2010) Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry 71:391-399
4. Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsycho-pharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137-162
5. McMurray RG, Zaldivar F, Galassetti P, Larson J, Eliakim A, Nemet D, Cooper DM (2007) Cellular immunity and inflammatory mediator responses to intense exercise in overweight children and adolescents. J Investig Med 55:120-129 (Pubitemid 47309347)
6. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446-457
7. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB (2007) Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1044-1053
8. Yirmiya R, Barak O, Avitsur R, Avitsur R, Gallily R, Weidenfeld J (1997) Intracerebral administration of Mycoplasma fermentans produces sickness behavior: role of prostaglandins. Brain Res 749:71-81 (Pubitemid 27096456)
9. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415
10. Uysal KT, Wiesbrock SM, Marino MV, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389:610-614 (Pubitemid 27446179)
11. Muller N, Schwarz MJ (2008) COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14:1452-1465 (Pubitemid 351982552)
12. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC (2009) COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity 17:1150-1157
13. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313-320 (Pubitemid 41175991)
14. Casarotto PC, Andreatini R (2007) Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 17:735-742 (Pubitemid 47432838)
15. Filip M, Cunningham KA (2003) Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin2C (5-HT2C) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306:734-743 (Pubitemid 36886175)
16. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336 (Pubitemid 8225714)
17. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72
18. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370 (Pubitemid 15123115)
19. Kamei J, Miyata S, Sunohara T, Kamei A, Shimada M, Ohsawa M (2008) Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 108:381-384
20. Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525-529 (Pubitemid 16145187)
21. Adeyemi OO, Yemitan OK, Taiwo AE (2006) Neurosedative and muscle-relaxant activities of ethyl acetate extract of Baphia nitidia AFZEL. J Ethnopharmacol 106:312-316
22. Trinder P (1969) Enzymatic method of glucose estimation. Ann Clin Biochem 6:24-33
23. Meittini F, Prencipe F, Bardelli G, Giannini G, Tarli P (1978) The 4-hydroxybenzoate/4-aminophenazone chromogenic system. Clin Chem 24:2161-2165
24. Buccolo G, David H (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 19:476-482
25. Koller A (1984) Total serum protein. In: Kaplan LA, Pesce AJ (eds) Clinical chemistry, theory, analysis, and correlation. Mosby Company, St. Louis, pp 1316-1319
26. Malnick SDH, Knobler H (2006) The medical complications of obesity. Q J Med 99:565-579 (Pubitemid 44540533)
27. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH (2009) Depression and anxiety among US adults: associations with body mass index. Int J Obes (Lond) 33:257-266
28. Sharma S, Fulton S (2012) Diet-induced obesity promotes depressive-like behavior that is associated with neural adaptations in brain reward circuitry. Int J Obes 37:382-389
29. Vogelzangs N, Kritchevsky SB, Beekman AT, Brenes GA, Newman AB, Satterfield S, Penninx BW (2010) Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry 71:391-399
30. Shelton RC, Miller AH (2011) Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci 13:41-53
31. Dantzer R (2009) Cytokine, sickness behavior and depression. Immunol Allergy Clin North Am 29:247-264
32. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE (2007) Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. NeuroImmunoModulation 14:65-71 (Pubitemid 47442983)
33. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F (2009) Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612:54-60
34. Almeida OP, Calver J, Jamrozik K, Hankey GJ, Flicker L (2009) Obesity and metabolic syndrome increases the risk of incident depression in older men: the health in men study. Am J Geriatr Psychiatry 17:889-898
35. Der-Avakian A, Markou A (2012) The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35:68-77
36. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238-245 (Pubitemid 34465544)
37. Hogg S (1996) A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21-30
38. Weiss SM, Wadsworth G, Fletcher A, Dourish CT (1998) Utility of ethological analysis to overcome locomotor confounds in elevated plus-maze of anxiety. Neurosci Biobehav Rev 23:265-271 (Pubitemid 29011628)
39. Pan A, Ye X, Franco OH, Li H, Yu Z, Zou S, Lin X (2006) Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord 109:75-82
40. Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torrens JI, Kravitz HM, Matthews KA (2004) Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27:2856-2862 (Pubitemid 39565049)
41. Lu S, Archer MC (2007) Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1. Exp Biol Med 232:643-653 (Pubitemid 46683390)
42. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97:2672-2679 (Pubitemid 26187355)
43. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, Nakao K (2011) Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 152:2634-2643